Last reviewed · How we verify

Yellow fever vaccine, Institut Pasteur

University of Oxford · FDA-approved active Biologic

The vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain.

The vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain. Used for Prevention of yellow fever in travelers to endemic regions, Prevention of yellow fever in at-risk populations in endemic areas.

At a glance

Generic nameYellow fever vaccine, Institut Pasteur
Also known asChildren sub-study
SponsorUniversity of Oxford
Drug classLive attenuated vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Yellow fever vaccine (Institut Pasteur strain) contains a weakened live yellow fever virus that replicates in vaccinated individuals without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing protective immunity against infection with wild-type yellow fever virus. A single dose typically confers lifelong immunity in most recipients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: